Latest news with #Reblozyl
Yahoo
4 days ago
- Business
- Yahoo
Why Income Investors Are Watching Bristol-Myers Squibb Company (BMY) in 2025
Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. A pharmacy shelves stocked with pharmaceutical drugs awaiting distribution. The company has dealt with some hurdles in the past, but it has secured several key new drug approvals in recent years. One of the most notable is Reblozyl, a treatment for anemia in individuals with beta-thalassemia, a rare blood disorder. In the first quarter, Reblozyl generated $478 million in sales, marking a 35% increase compared to the same period last year. Bristol-Myers Squibb Company (NYSE:BMY)'s revenue for the year came in at $11.2 billion, which, though, fell by 5.6% from the same period last year, beat analysts' estimates by $494.6 million. The company's cash position also remained strong, with cash and cash equivalents of $10.9 billion, up from $10.34 billion at the end of December 2024. Bristol-Myers Squibb Company (NYSE:BMY) has raised its full-year revenue forecast from around $45.5 billion to a new range of about $45.8 billion to $46.8 billion. This upward revision reflects strong results from its Growth Portfolio, stronger-than-anticipated Legacy Portfolio sales in the first quarter of 2025, and a positive foreign exchange impact of roughly $500 million. Bristol-Myers Squibb Company (NYSE:BMY) offers a quarterly dividend of $0.62 per share and has a dividend yield of 5.18%, as of July 17. The company has been rewarding its shareholders with growing dividends for the past 16 years. While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
Yahoo
4 days ago
- Business
- Yahoo
Why Income Investors Are Watching Bristol-Myers Squibb Company (BMY) in 2025
Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. A pharmacy shelves stocked with pharmaceutical drugs awaiting distribution. The company has dealt with some hurdles in the past, but it has secured several key new drug approvals in recent years. One of the most notable is Reblozyl, a treatment for anemia in individuals with beta-thalassemia, a rare blood disorder. In the first quarter, Reblozyl generated $478 million in sales, marking a 35% increase compared to the same period last year. Bristol-Myers Squibb Company (NYSE:BMY)'s revenue for the year came in at $11.2 billion, which, though, fell by 5.6% from the same period last year, beat analysts' estimates by $494.6 million. The company's cash position also remained strong, with cash and cash equivalents of $10.9 billion, up from $10.34 billion at the end of December 2024. Bristol-Myers Squibb Company (NYSE:BMY) has raised its full-year revenue forecast from around $45.5 billion to a new range of about $45.8 billion to $46.8 billion. This upward revision reflects strong results from its Growth Portfolio, stronger-than-anticipated Legacy Portfolio sales in the first quarter of 2025, and a positive foreign exchange impact of roughly $500 million. Bristol-Myers Squibb Company (NYSE:BMY) offers a quarterly dividend of $0.62 per share and has a dividend yield of 5.18%, as of July 17. The company has been rewarding its shareholders with growing dividends for the past 16 years. While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Reuters
5 days ago
- Business
- Reuters
Bristol Myers drug fails main goal in cancer-linked anemia trial
July 18 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main goal of a late-stage trial to treat anemia caused by a rare bone marrow cancer. The study did not achieve statistically significant results in helping patients with myelofibrosis become free from red blood cell transfusions for any 12-week period during the first 24 weeks of treatment. The miss could signal long-term challenges for the company as future revenues rely on expanding the use of key drugs, Raymond James analysts said. They noted several missed opportunities for broader approvals, including Sotyktu in ulcerative colitis and Crohn's, Camzyos in heart disease, Opdualag in early-stage melanoma, and Cobenfy in schizophrenia. The company, however, remained upbeat about the drug's prospects and said more patients receiving Reblozyl saw a reduction in the number of transfusions needed and an increase in hemoglobin levels, a key measure of anemia. The side effects seen in the trial were similar to those previously reported for Reblozyl. "It is promising to see that Reblozyl led to clinically relevant improvement of anemia for patients with myelofibrosis," said Anne Kerber, head of hematology, oncology, and cell therapy at Bristol Myers. Reblozyl is already approved for certain types of anemia related to other blood disorders, including myelodysplastic syndromes and beta-thalassemia. Bristol Myers recorded $1.77 billion in global sales of Reblozyl in 2024. The late-stage trial in myelofibrosis patients tested Reblozyl with a Janus kinase inhibitor drug, a class of medicines that works by slowing down the immune system. Myelofibrosis is a type of cancer that scars the bone marrow, inhibiting production of healthy blood cells. Reblozyl's failure in the trial might be positive for Disc Medicine (IRON.O), opens new tab, as investors might look favorably at its hepcidin portfolio, given the strength of data and limited treatment options, BMO Capital Markets analysts said. Shares of Disc Medicine rose 4%, while Bristol Myers slipped 1% in morning trading.
Reuters
5 days ago
- Business
- Reuters
Bristol Myers' drug fails main goal in cancer-related anemia trial
July 18 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main goal of a late-stage trial to treat anemia due to a rare bone marrow cancer. The study did not achieve statistically significant results in helping myelofibrosis patients become free from red blood cell transfusions for any 12-week period during the first 24 weeks of treatment. However, more patients receiving Reblozyl saw a reduction in the number of transfusions needed and an increase in hemoglobin levels, a key measure of anemia, the company said. The side effects seen in the trial were similar to those previously reported for Reblozyl. "It is promising to see that Reblozyl led to clinically relevant improvement of anemia for patients with myelofibrosis," said Anne Kerber, head of hematology, oncology, and cell therapy at Bristol Myers. The company remains confident in the treatment's potential to address unmet need, Kerber added. The late-stage trial in myelofibrosis patients tested Reblozyl with a Janus kinase inhibitor drug, a class of medicines that works by slowing down the immune system. Myelofibrosis is a type of cancer, in which the bone marrow becomes scarred and doesn't produce enough healthy blood cells. Reblozyl is already approved for certain types of anemia related to other blood disorders, including myelodysplastic syndromes and beta-thalassemia. Bristol Myers recorded $1.77 billion in global sales of Reblozyl in 2024. Other approved treatments for myelofibrosis-associated anemia include Incyte's (INCY.O), opens new tab Jakafi and British drugmaker GSK's (GSK.L), opens new tab Ojjaara. Reblozyl's failure in the trial might be positive for Disc Medicine (IRON.O), opens new tab, as investors might look favorably at its hepcidin portfolio, given the strength of data and limited treatment options, BMO Capital Markets analysts said.
Reuters
5 days ago
- Business
- Reuters
Bristol Myers' drug fails main goal in late-stage trial for cancer-related anemia
July 18 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main goal of a late-stage trial to treat anemia due to a rare bone marrow cancer. The study did not achieve statistically significant results in helping patients become free from red blood cell transfusions for any 12-week period during the first 24 weeks of treatment. However, more patients receiving Reblozyl saw a reduction in the number of transfusions needed and an increase in hemoglobin levels, a key measure of anemia, the company said. The side effects seen in the trial were similar to those previously reported for Reblozyl. Reblozyl is already approved for certain types of anemia related to other blood disorders, including myelodysplastic syndromes and beta thalassemia. Bristol Myers recorded $1.77 billion in global sales of Reblozyl in 2024. In the late-stage trial, the drug was being tested to treat anemia in myelofibrosis patients with a Janus kinase inhibitor drug, a class of medicines that works by slowing down the immune system. Myelofibrosis is a type of cancer, in which the bone marrow becomes scarred and doesn't produce enough healthy blood cells.
